Radiopharmaceutical chemistry
The Radiopharmacy Center of the Clinic and Polyclinic for Nuclear Medicine at LMU in Großhadern offers the opportunity to produce radioactive drugs in accordance with GMP (Good Manufacturing Practice) standards and current radiation protection and pharmaceutical guidelines. The radiopharmacy building built in 2013 with its own cyclotron and in-house pharmaceutical production is operated in cooperation with AAA München GmbH as part of a public-private partnership (PPP) and is the basis for providing biomarkers for diagnostics and radiotherapeutics for patient-individualized therapy as required and in the highest quality. This ensures that patient care is provided at the highest possible level. The Radiopharmacy Center offers the best conditions for conducting clinical studies as well as preclinical and basic radiopharmaceutical research.
The following tracers, among others, are produced for preclinical or clinical studies:
- 68Ga-PSMA, 18F-PSMA, 177Lu-PSMA and 225Ac-PSMA
- 68Ga-TATE, 68Ga-TOC and 177Lu-TATE
- 11C-Flumazenil
- 18F-FLT
- 18F-ML10
- 18F-DMFP and 18F-FP
- 18F-MPPF
- 18F-GE180
- 18F-Flutemetamol
- 18F-Florbetaben
- 18F-THK5117 and 18F-GE216 (18F-THK5351)
- 18F-UCB-H
Different platforms from GE Healthcare, Scintomics, Elysia-Raytest, Comecer and Trasis are available for the production of the tracers.
